Immunotherapy or biological therapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies. Immunotherapy is under preliminary research for its potential to treat various forms of cancer.
The Crafoord Prize is an annual science prize established in 1980 by Holger Crafoord, a Swedish industrialist, and his wife Anna-Greta Crafoord. The Prize is awarded in partnership between the Royal Swedish Academy of Sciences and the Crafoord Foundation in Lund. The Academy is responsible for selecting the Crafoord Laureates. The prize is awarded in four categories: astronomy and mathematics; geosciences; biosciences, with particular emphasis on ecology; and polyarthritis, the disease from which Holger severely suffered in his last years.
The regulatory T cells (Tregs or Treg cells), formerly known as suppressor T cells, are a subpopulation of T cells that modulate the immune system, maintain tolerance to self-antigens, and prevent autoimmune disease. Treg cells are immunosuppressive and generally suppress or downregulate induction and proliferation of effector T cells. Treg cells express the biomarkers CD4, FOXP3, and CD25 and are thought to be derived from the same lineage as naïve CD4+ cells. Because effector T cells also express CD4 and CD25, Treg cells are very difficult to effectively discern from effector CD4+, making them difficult to study. Research has found that the cytokine transforming growth factor beta (TGF-β) is essential for Treg cells to differentiate from naïve CD4+ cells and is important in maintaining Treg cell homeostasis.
FOXP3, also known as scurfin, is a protein involved in immune system responses. A member of the FOX protein family, FOXP3 appears to function as a master regulator of the regulatory pathway in the development and function of regulatory T cells. Regulatory T cells generally turn the immune response down. In cancer, an excess of regulatory T cell activity can prevent the immune system from destroying cancer cells. In autoimmune disease, a deficiency of regulatory T cell activity can allow other autoimmune cells to attack the body's own tissues.
Timothy "Tim" A. Springer is an immunologist and the Latham Family Professor at Harvard Medical School. He is also a professor at the Department of Biological Chemistry and Molecular Pharmacology and of the Division of Medical Sciences, and a Senior Investigator at the Research Program in Cellular and Molecular Medicine of the Boston Children's Hospital. Springer is best known for discovering the first integrins, LFA-1, and intercellular adhesion molecules (ICAMs), and for elucidating how these cell adhesion molecules function in the immune system. In recent years, Springer's research interest has expanded to malaria, transforming growth factor beta (TGF-β) signaling, and von Willebrand factor.
T helper 3 cells (Th3) are a subset of T lymphocytes with immunoregulary and immunosuppressive functions, that can be induced by administration of foreign oral antigen. Th3 cells act mainly through the secretion of anti-inflammatory cytokine transforming growth factor beta (TGF-β). Th3 have been described both in mice and human as CD4+FOXP3− regulatory T cells. Th3 cells were first described in research focusing on oral tolerance in the experimental autoimmune encephalitis (EAE) mouse model and later described as CD4+CD25−FOXP3−LAP+ cells, that can be induced in the gut by oral antigen through T cell receptor (TCR) signalling.
Sir Marc Feldmann,, is an Australian-educated British immunologist. He is a professor at the University of Oxford and a senior research fellow at Somerville College, Oxford.
Benaroya Research Institute (BRI) is a Seattle, Washington non-profit organization that conducts medical research on many diseases and immune disorders, including autoimmune disease. It is affiliated with Virginia Mason Health System, and is located on the campus of Virginia Mason Medical Center.
James Patrick Allison is an American immunologist and Nobel laureate who holds the position of professor and chair of immunology and executive director of immunotherapy platform at the MD Anderson Cancer Center at the University of Texas.
Zelig Eshhar is an Israeli immunologist at the Weizmann Institute of Science and the Tel Aviv Sourasky Medical Center. He was Chairman of the Department of Immunology at the Weizmann Institute twice, in the 1990s and 2000s.
Shimon Sakaguchi is an immunologist and a Distinguished Professor of Osaka University. He is best known for the discovery of regulatory T cells and to describe their role in the immune system. This discovery is used in the treatment of cancer and autoimmune diseases.
Jeffrey A. Bluestone is the A.W. and Mary Margaret Clausen Distinguished Professor Emeritus of Metabolism and Endocrinology at the University of California, San Francisco, and was, for a number of years, an earlier executive vice chancellor and provost of that university. He began the UCSF affiliation in 2000, after earlier extended positions at the NCI-NIH, and at The University of Chicago. Bluestone earned his undergraduate and masters degrees in microbiology from Rutgers State University, and his doctoral degree in immunology from Cornell Graduate School of Medical Science. His current research is focused on understanding T cell activation and immune tolerance in autoimmunity and organ transplantation. In April 2016, he co-founded and served as the president and CEO of the Parker Institute for Cancer Immunotherapy,. In 2019, he co-founded and is Chief Executive Officer and President of Sonoma Biotherapeutics.
Alexander Rudensky is an immunologist at Memorial Sloan Kettering Cancer Center known for his research on regulatory T cells and the transcription factor Foxp3.
Alexander Marson is an American biologist and infectious disease doctor who specializes in genetics, human immunology, and genome engineering. He is the Director of the Gladstone-UCSF Institute of Genomic Immunology, and a tenured Professor with a dual appointment in the Department of Medicine and the Department of Microbiology & Immunology at the University of California, San Francisco (UCSF).
Ethan Menahem Shevach is an immunologist at the National Institute of Allergy and Infectious Diseases (NIAID) in Bethesda, Maryland.
Jane L. Grogan is an Australian-born, US-based scientist specializing in immunology and cancer research.
Uğur Şahin is a German oncologist and immunologist. He is the founder and CEO of BioNTech, which developed one of the major vaccines against COVID-19. His main fields of research are cancer research and immunology.
Daniel L. Kastner is an American physician and researcher specialising in the genetics of autoinflammatory disorders. He is scientific director of the National Human Genome Research Institute, where he is a National Institutes of Health Distinguished Investigator. He was awarded the 2021 Crafoord Prize for Polyarthritis for his pioneering work on autoinflammatory diseases.
Vijay K. Kuchroo is an Indian-American immunologist and serial entrepreneur. He is the Samuel L. Wasserstrom chair of Neurology at Harvard Medical School, and Brigham and Women's Hospital. He is also the director of the Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women's Hospital in Boston, Massachusetts.
Philip Greenberg is a professor of medicine, oncology, and immunology at the University of Washington and head of program in immunology at the Fred Hutchinson Cancer Research Center. His research is centered around T cell biology and therapeutic cell therapies. He is a co-founder of Juno Therapeutics.
